Biocryst Pharmaceuticals (BCRX) Non-Current Debt (2011 - 2026)

Biocryst Pharmaceuticals has reported Non-Current Debt for 16 years, with the latest figure at $395.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt rose 25.3% year-over-year to $395.2 million; the trailing twelve-month figure through Mar 2026 stood at $395.2 million (up 25.3% YoY), and the FY2024 full-year result was $314.9 million, up 3.84% from the prior year.
• Non-Current Debt for Q1 2026 stood at $395.2 million, up from $194.4 million in the prior quarter.
• The five-year high for Non-Current Debt was $395.2 million in Q1 2026, with the low at $140.2 million in Q1 2022.
• Historically, Non-Current Debt has averaged $266.7 million across 5 years, with a median of $295.6 million in 2023.
• Annual changes were most pronounced in 2023 — Non-Current Debt soared 102.87% — and 2025, when it slumped 38.17%.
• Biocryst Pharmaceuticals' Non-Current Debt stood at $231.6 million in 2022, then soared by 30.92% to $303.2 million in 2023, then gained by 3.84% to $314.9 million in 2024, then tumbled by 38.27% to $194.4 million in 2025, then jumped by 103.33% to $395.2 million in 2026.
• The last three Non-Current Debt figures came in at $395.2 million (Q1 2026), $194.4 million (Q3 2025), and $242.8 million (Q2 2025), per Business Quant data.